Patents by Inventor Bilha Schechter

Bilha Schechter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9926564
    Abstract: Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.
    Type: Grant
    Filed: October 27, 2013
    Date of Patent: March 27, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yosef Yarden, Michael Sela, Georg Mahlknecht, Ruth Maron, Bilha Schechter
  • Patent number: 9358288
    Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: June 7, 2016
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Michael Sela, Yosef Yarden, Bilha Schechter, Tsipi Ben-Kasus
  • Publication number: 20150307883
    Abstract: Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.
    Type: Application
    Filed: October 27, 2013
    Publication date: October 29, 2015
    Applicant: Yeda Research and Development Co. Ltd. at Weizmann Institute of Science
    Inventors: Yosef YARDEN, Michael SELA, Georg MAHLKNECHT, Ruth MARON, Bilha SCHECHTER
  • Patent number: 9040047
    Abstract: An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: May 26, 2015
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michael Sela, Yosef Yarden, Bilha Schechter, Ruth Maron
  • Publication number: 20150056216
    Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.
    Type: Application
    Filed: November 10, 2014
    Publication date: February 26, 2015
    Inventors: MICHAEL SELA, YOSEF YARDEN, BILHA SCHECHTER, TSIPI BEN-KASUS
  • Patent number: 8883149
    Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: November 11, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michael Sela, Yosef Yarden, Bilha Schechter, Tsipi Ben-Kasus
  • Publication number: 20140086917
    Abstract: An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.
    Type: Application
    Filed: May 16, 2012
    Publication date: March 27, 2014
    Applicant: Yeda Research and Development Co. Ltd
    Inventors: Michael Sela, Yosef Yarden, Bilha Schechter, Ruth Maron
  • Publication number: 20110171206
    Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.
    Type: Application
    Filed: August 19, 2009
    Publication date: July 14, 2011
    Applicant: Yeda Research And Development Co., Ltd. at the Weizmann Institute of Science
    Inventors: Michael Sela, Yosef Yarden, Bilha Schechter, Tsipi Ben-Kasus
  • Patent number: 6694171
    Abstract: A delivery system and method for targeting a contrast agent to tissues and organs for improved diagnosis of tumors and for prognosis and follow-up of cancer therapy by X-ray imaging. The delivery system includes a conjugate or complex of a macromolecular carrier and a contrast agent selected from the group consisting of: (a) a compound having a heavy element with an atomic number in the range of 75 to 92, and (b) a compound having an element with a property of an abrupt change in its X-ray attenuation coefficient within the energy range used for radiography, said macromolecular carrier of said conjugate or complex being optionally linked to a specific tissue marker molecule.
    Type: Grant
    Filed: March 6, 2000
    Date of Patent: February 17, 2004
    Assignee: Yeda Research and Development
    Inventors: Amos Breskin, Rachel Chechik, Zvi Paltiel, Bilha Schechter, Abraham Warshawsky, Abraham Shanzer, Michal Neeman
  • Patent number: 6638508
    Abstract: The present invention relates to avidin-type molecules having 2,4,6-trinitrophenyl or lactosyl groups or being complexed with an antibody specific to the avidin-type molecule, which shifts the biodistribution pattern in tissues and organs to the liver, where these molecules accumulate at high levels over several days. These modified avidin-type molecules provide a means for delivery of diagnostic and therapeutic agents, including radionuclides to the liver and cells of the reticuloendothelial system (RES) for diagnosing and treating hepatic disorders and disorders of the RES.
    Type: Grant
    Filed: June 19, 1998
    Date of Patent: October 28, 2003
    Assignee: Yeda Research and Development Co., Ltd.
    Inventors: Bilha Schechter, Ruth Arnon, Meir Wilchek
  • Publication number: 20020009416
    Abstract: The present invention relates to avidin-type molecules having 2,4,6-trinitrophenyl or lactosyl groups or being complexed with an antibody specific to the avidin-type molecule, which shifts the biodistribution pattern in tissues and organs to the liver, where these molecules accumulate at high levels over several days. These modified avidin-type molecules provide a means for delivery of diagnostic and therapeutic agents, including radionuclides to the liver and cells of the reticuloendothelial system (RES) for diagnosing and treating hepatic disorders and disorders of the RES.
    Type: Application
    Filed: June 19, 1998
    Publication date: January 24, 2002
    Inventors: BILHA SCHECHTER, RUTH ARNON, MEIR WILCHEK